24(R),25-Epoxycholesterol | 93528-37-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 24(R),25-Epoxycholesterol
• 英文别名: (3S,8S,9S,10R,13R,14S,17R)-17-((R)-4-((R)-3,3-Dimethyloxiran-2-yl)butan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol；(3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-4-[(2R)-3,3-dimethyloxiran-2-yl]butan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 93528-37-1
• 化学式: C₂₇H₄₄O₂
• 分子量: 400.645
• InChiKey: OSENKJZWYQXHBN-PJXSLZQESA-N

物化性质

• 沸点：
  496.4±18.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  32.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (3beta)-3-(叔-丁基二甲基硅烷基)氧基-胆-5-烯-24-酸甲酯 在 吡啶 、 四氧化锇 、 正丁基锂 、 Hydroquinone 1,4-phthalazinediyl diether 、 四丁基氟化铵 、 双(三甲基硅烷基)氨基钾 、 二异丁基氢化铝 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 甲苯 、 叔丁醇 为溶剂， 反应 52.0h， 生成 24(R),25-Epoxycholesterol
  参考文献：
  名称：

  Stereocontrolled syntheses of 24(S),25-epoxycholesterol and related oxysterols for studies on the activation of LXR receptors

  摘要：

  Efficient syntheses are described of desmosterol (4), the corresponding 24(S),25 epoxide (6) and various analogs of 6 for evaluation as ligands and functional activators of LXR receptors. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)02181-9

文献信息

• Use of endogenous metabolites for early diagnosing sepsis
  申请人：BIOCRATES Life Sciences AG

  公开号：EP2339352A1

  公开（公告）日：2011-06-29

  The present invention relates to a use of one or a plurality of endogenous target metabolites for predicting a likelihood of an onset of a sepsis from a biological sample of a mammalian subject in vitro, wherein said endogenous target metabolites have a molecular mass less than 1500 Da and are selected from the group of oxysterols.

  本发明涉及使用一种或多种内源性目标代谢物来预测体外哺乳动物生物样本中败血症发生的可能性，其中所述内源性目标代谢物的分子质量小于 1500 Da，并且选自氧甾醇组。
• Treatment for age-related macular degeneration (AMD)
  申请人：——

  公开号：US20030162758A1

  公开（公告）日：2003-08-28

  The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

  本发明利用与动脉粥样硬化类似的致病机制的调节来治疗老年性黄斑变性。在更具体的实施方案中，反向胆固醇转运成分，如转运体和高密度脂蛋白组分，被用作老年性黄斑变性的诊断和治疗靶标。在一个具体的实施方案中，视网膜色素上皮和/或布鲁氏膜的脂质含量降低。
• Treatments for age-related macular degeneration (AMD)
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20030229062A1

  公开（公告）日：2003-12-11

  The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

  本发明利用与动脉粥样硬化类似的致病机制的调节来治疗老年性黄斑变性。在更具体的实施方案中，反向胆固醇转运成分，如转运体和高密度脂蛋白组分，被用作老年性黄斑变性的诊断和治疗靶标。在一个具体的实施方案中，视网膜色素上皮和/或布鲁氏膜的脂质含量降低。
• Compositions and methods for modulating HDL cholesterol and triglyceride levels
  申请人：——

  公开号：US20040137423A1

  公开（公告）日：2004-07-15

  The invention provides methods for identifying agents that modulate HDL-levels in animals by evaluating the ability of LXR-modulating agents to increase ABCA1-gene expression in a cell as well as using such agents to treat conditions involving lower than normal HDL-levels, higher than normal triglyceride levels and the like.

  本发明提供了通过评估 LXR 调节药剂增加细胞中 ABCA1 基因表达的能力，以及使用此类药剂治疗高密度脂蛋白水平低于正常、甘油三酯水平高于正常等病症，从而确定调节动物体内高密度脂蛋白水平的药剂的方法。
• Efficient, Stereoselective Synthesis of 24(<i>S</i>),25-Epoxycholesterol
  作者：Nicholas C. O. Tomkinson、Timothy M. Willson、Jonathon S. Russel、Thomas A. Spencer

  DOI：10.1021/jo981753v

  日期：1998.12.1

  Efficient, stereoselective syntheses of 24(S),25-epoxycholesterol (1) have been developed starting from cholenic acid (4) or stigmasterol (8), both featuring as the key step Sharpless asymmetric dihydroxylation of desmosterol acetate (2). This work permits preparation of gram quantities of 1 for further evaluation as a natural regulator of cholesterol metabolism, specifically, e.g., as a ligand for the LXR alpha nuclear receptor.